Sriram Sridhar
Research Subjects
Research Interests
Sriram Sridhar has a total of 27 co-authors. Here are the top co-authors by number of shared publications:
Ashok Gupta
AstraZeneca, Gaithersburg, MD
1 shared publicationBrandon W. Higgs
AstraZeneca, Gaithersburg, MD
1 shared publicationChris Morehouse
AstraZeneca, Gaithersburg, MD
1 shared publication- Gautam Damera
MedImmune LLC, One MedImmune Way, #4552B, Gaithersburg, MD, USA
1 shared publication Hao Liu
AstraZeneca, Gaithersburg, MD
1 shared publication- Hao Liu
Shanghai Qilu Pharmaceutical R&D Center Ltd., China
1 shared publication
Latest Publications
- Open Access
- 1 November 2019
- Published by Elsevier in Clinical Lung Cancer
- Vol. 20 (6) , e601-e608
Prognostic Significance of Liver Metastasis in Durvalumab-Treated Lung Cancer Patients
- 1 November 2019
- Published by Elsevier in Clinical Lung Cancer
- Vol. 20 (6) , e601-e608
Open AccessPrognostic Significance of Liver Metastasis in Durvalumab-Treated Lung Cancer Patients
- 28 September 2019
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 54 (suppl 63) , RCT3785
Tezepelumab decreases matrix remodelling and inflammatory pathways in patients with asthma
Background: Tezepelumab, a human monoclonal antibody that selectively blocks thymic stromal lymphopoietin interaction (TSLP) with its receptor, improved clinical outcomes vs. placebo in patients with severe, uncontrolled asthma (Phase 2b PATHWAY study [NCT02054130]). Proteomics analysis was performed to further elucidate mechanisms of tezepelumab activity in patients with asthma. Aim: To determine which serum proteins are altered by tezepelumab. Methods: Patients were randomised to tezepelumab-treatment arms or placebo (Corren et al. NEJM 2017;377:936–46). Serum protein levels were assessed at baseline and at multiple post-treatment timepoints up to Week 52 using the Myriad Rules Based Medicine (RBM) and SomaLogic platforms (122 and 1305 analytes, respectively). Significant changes were determined by ANOVA and t-tests at each timepoint, with percent changes from baseline also being assessed. We also explored associations between baseline levels of RBM proteins and clinical biomarkers. Results: Levels of matrix remodelling (MMP-10, periostin), eosinophil-related (IL5RA, PAPP‑A), IgE and TARC proteins decreased significantly post-treatment (>10% change in tezepelumab vs. placebo at Week 52, pNO levels. Conclusions: Tezepelumab led to a decrease in biomarkers of inflammation and matrix remodelling, which were correlated with bEOS and FENO levels at baseline. Modulation of matrix remodelling proteins may reflect a novel mechanism of action for tezepelumab in addition to the inhibition of airway inflammation. Co-sponsored by MedImmune, a member of the AstraZeneca Group, and Amgen Inc.
- 28 September 2019
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 54 (suppl 63) , RCT3785
Tezepelumab decreases matrix remodelling and inflammatory pathways in patients with asthma
Background: Tezepelumab, a human monoclonal antibody that selectively blocks thymic stromal lymphopoietin interaction (TSLP) with its receptor, improved clinical outcomes vs. placebo in patients with severe, uncontrolled asthma (Phase 2b PATHWAY study [NCT02054130]). Proteomics analysis was performed to further elucidate mechanisms of tezepelumab activity in patients with asthma. Aim: To determine which serum proteins are altered by tezepelumab. Methods: Patients were randomised to tezepelumab-treatment arms or placebo (Corren et al. NEJM 2017;377:936–46). Serum protein levels were assessed at baseline and at multiple post-treatment timepoints up to Week 52 using the Myriad Rules Based Medicine (RBM) and SomaLogic platforms (122 and 1305 analytes, respectively). Significant changes were determined by ANOVA and t-tests at each timepoint, with percent changes from baseline also being assessed. We also explored associations between baseline levels of RBM proteins and clinical biomarkers. Results: Levels of matrix remodelling (MMP-10, periostin), eosinophil-related (IL5RA, PAPP‑A), IgE and TARC proteins decreased significantly post-treatment (>10% change in tezepelumab vs. placebo at Week 52, pNO levels. Conclusions: Tezepelumab led to a decrease in biomarkers of inflammation and matrix remodelling, which were correlated with bEOS and FENO levels at baseline. Modulation of matrix remodelling proteins may reflect a novel mechanism of action for tezepelumab in addition to the inhibition of airway inflammation. Co-sponsored by MedImmune, a member of the AstraZeneca Group, and Amgen Inc.
- Open Access
- 18 January 2019
- Published by Springer Nature in Respiratory Research
- Vol. 20 (1) , 14
Modulation of blood inflammatory markers by benralizumab in patients with eosinophilic airway diseases
Benralizumab, a humanized, afucosylated, monoclonal antibody that targets interleukin-5 receptor α, depletes eosinophils and basophils by enhanced antibody-dependent cell-mediated cytotoxicity. It demonstrated efficacy for patients with moderate to severe asthma and, in a Phase IIa trial, for chronic obstructive pulmonary disease (COPD) with eosinophilic inflammation. We investigated effects of benralizumab 100 mg every 8 weeks (first three doses every 4 weeks) subcutaneous on blood inflammatory markers through proteomic and gene-expression analyses collected during two Phase II studies of patients with eosinophilic asthma and eosinophilic COPD. Serum samples for proteomic analysis and whole blood for gene expression analysis were collected at baseline and 52 weeks (asthma study) or 32 weeks (COPD study) post-treatment. Proteomic analyses were conducted on a custom set of 90 and 147 Rules-Based Medicine analytes for asthma and COPD, respectively. Gene expression was profiled by Affymetrix Human Genome U133 plus 2 arrays (~ 54 K probes). Gene set variation analysis (GSVA) was used to determine transcriptomic activity of immune signatures. Treatment-related differences between analytes, genes, and gene signatures were analyzed for the overall population and for patient subgroups stratified by baseline blood eosinophil count (eosinophil-high [≥300 cells/μL] and eosinophil-low [< 300 cells/μL]) via t-test and repeated measures analysis of variance. Eosinophil chemokines eotaxin-1 and eotaxin-2 were significantly upregulated (false discovery rate [FDR] < 0.05) by approximately 2.1- and 1.4-fold in the asthma study and by 2.3- and 1.7-fold in the COPD study following benralizumab treatment. Magnitude of upregulation of these two chemokines was greater for eosinophil-high patients than eosinophil-low patients in both studies. Benralizumab was associated with significant reductions (FDR < 0.05) in expression of genes associated with eosinophils and basophils, such as CLC, IL-5Rα, and PRSS33; immune-signaling complex genes (FCER1A); G-protein–coupled receptor genes (HRH4, ADORA3, P2RY14); and further immune-related genes (ALOX15 and OLIG2). The magnitude of downregulation of gene expression was greater for eosinophil-high than eosinophil-low patients. GSVA on immune signatures indicated significant treatment reductions (FDR < 0.05) in eosinophil-associated signatures. Benralizumab is highly selective, modulating blood proteins or genes associated with eosinophils or basophils. Modulated protein and gene expression patterns are most prominently altered in eosinophil-high vs. eosinophil-low patients. NCT01227278 and NCT01238861 .
- 18 January 2019
- Published by Springer Nature in Respiratory Research
- Vol. 20 (1) , 14
Open AccessModulation of blood inflammatory markers by benralizumab in patients with eosinophilic airway diseases
Benralizumab, a humanized, afucosylated, monoclonal antibody that targets interleukin-5 receptor α, depletes eosinophils and basophils by enhanced antibody-dependent cell-mediated cytotoxicity. It demonstrated efficacy for patients with moderate to severe asthma and, in a Phase IIa trial, for chronic obstructive pulmonary disease (COPD) with eosinophilic inflammation. We investigated effects of benralizumab 100 mg every 8 weeks (first three doses every 4 weeks) subcutaneous on blood inflammatory markers through proteomic and gene-expression analyses collected during two Phase II studies of patients with eosinophilic asthma and eosinophilic COPD. Serum samples for proteomic analysis and whole blood for gene expression analysis were collected at baseline and 52 weeks (asthma study) or 32 weeks (COPD study) post-treatment. Proteomic analyses were conducted on a custom set of 90 and 147 Rules-Based Medicine analytes for asthma and COPD, respectively. Gene expression was profiled by Affymetrix Human Genome U133 plus 2 arrays (~ 54 K probes). Gene set variation analysis (GSVA) was used to determine transcriptomic activity of immune signatures. Treatment-related differences between analytes, genes, and gene signatures were analyzed for the overall population and for patient subgroups stratified by baseline blood eosinophil count (eosinophil-high [≥300 cells/μL] and eosinophil-low [< 300 cells/μL]) via t-test and repeated measures analysis of variance. Eosinophil chemokines eotaxin-1 and eotaxin-2 were significantly upregulated (false discovery rate [FDR] < 0.05) by approximately 2.1- and 1.4-fold in the asthma study and by 2.3- and 1.7-fold in the COPD study following benralizumab treatment. Magnitude of upregulation of these two chemokines was greater for eosinophil-high patients than eosinophil-low patients in both studies. Benralizumab was associated with significant reductions (FDR < 0.05) in expression of genes associated with eosinophils and basophils, such as CLC, IL-5Rα, and PRSS33; immune-signaling complex genes (FCER1A); G-protein–coupled receptor genes (HRH4, ADORA3, P2RY14); and further immune-related genes (ALOX15 and OLIG2). The magnitude of downregulation of gene expression was greater for eosinophil-high than eosinophil-low patients. GSVA on immune signatures indicated significant treatment reductions (FDR < 0.05) in eosinophil-associated signatures. Benralizumab is highly selective, modulating blood proteins or genes associated with eosinophils or basophils. Modulated protein and gene expression patterns are most prominently altered in eosinophil-high vs. eosinophil-low patients. NCT01227278 and NCT01238861 .